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Abstract: Background: candidiasis is the primary fungal infection encountered in patients undergoing
prolonged hospitalization, and the fourth leading cause of nosocomial bloodstream infections.
One of the most important Candida spp. virulence factors is the ability to form biofilms, which are
extremely refractory to antimicrobial therapy and very difficult to treat with the traditional antifungal
therapies. It is known that the prophylaxis or treatment of a systemic candidiasis are recurrently
taken without considering the possibility of a Candida spp. biofilm-related infections. Therefore, it is
important to assess the effectiveness of the available drugs and which formulations have the best
performance in these specific infections. Methods: 24-h-biofilms of four Candida spp. and their
response to two amphotericin B (AmB) pharmaceutical formulations (liposomal and deoxycholate)
were evaluated. Results: generally, Candida glabrata was the less susceptible yeast species to both
AmBs. MBECs revealed that it is therapeutically more appealing to use AmB-L than AmB-Deox for
all Candida spp. biofilms, since none of the determined concentrations of AmB-L reached 10% of
the maximum daily dose, but both formulations showed a very good capacity in the biomass
reduction. Conclusions: the liposomal formulation presents better performance in the eradication of
the biofilm cells for all the species in comparison with the deoxycholate formulation.
Keywords: amphotericin B; liposomal; deoxycholate; Candida spp.; biofilms; drug resistance
1. Introduction
Infections caused by Candida spp. have increased significantly in the past 30 years, becoming
a substantial cause of morbidity and mortality. This is particularly critical in immunologically
compromised individuals, and in patients submitted to continuous treatment with broad-spectrum
antibiotics, to invasive procedures, and with medically implanted devices, which can cause both
superficial and systemic infections [1,2]. Although Candida albicans is, generally, the most frequently
isolated species, there has also been a noteworthy upsurge in the frequency of non-Candida albicans
Candida (NCAC) species, such as Candida glabrata, Candida parapsilosis and Candida tropicalis [3].
Candida spp. pathogenicity is mediated by a number of virulence factors, including the ability to adhere
to medical devices and to host cells, which often leads to the formation of biofilms [4]. Biofilms are
biological communities with an extraordinary degree of organization, in which microorganisms
form structured, coordinated, and functional communities, embedded in a self-created extracellular
matrix [1,2,5]. The formation of Candida spp. biofilms raises significant clinical issues because of
an additional increase in antifungal drug resistance, as well as increased evasion of host immune
defences. Furthermore, biofilm development on medical devices can cause the failure of the device
and may turn into a source of future infection [6–8].
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Polyenes are among the most effective drugs for the treatment of systemic Candida spp.
infections, specifically AmB [9,10]. AmB binds to the ergosterol of the fungal cell membrane,
establishing transmembrane aggregate pores, causing membrane depolarization with a subsequent
increase in membrane permeability to monovalent protons and cations. This allows the passage
of intracellular molecules to the external environment, initiating an osmotic imbalance and, finally,
cell death [11–13]. This drug, produced by Streptomyces nodosus, is part of the macrolides class, and is
characterized by a macrocyclic ring lactone, with a hydrophobic and one hydrophilic domain, giving
it an amphipathic characteristic that confers low solubility in aqueous solutions at physiological pH.
With low bioavailability via oral administration, AmB is a highly hydrophobic weak base, with a low
aqueous solubility of approximately 1 ng/mL at pH 7 [14,15], needing to beproduced as a complex
with another agent to enable its clinical use, assodium deoxycholate. The possible administration
routes are intravenous, intra-articular, intravesical, intrathecal, in injuries and applied in surgical
sites [12,13,16].
AmB deoxycholate (AmB-Deox) has been used during recent years due to the rise in the number
of immunosuppressed patients suffering invasive fungal infections, but has been related to a high
rate of side effects, particularly renal toxicity [13,17]. Therefore, other formulations have been
developed: a lipid formulation (liposomal, AmBisome®, Gilead Sciences, Foster City, CA, USA),
a lipid complex (Abelcet®, Sigma Tau Pharmaceuticals, Pomezia, Italy), and a colloidal suspension
(Amphocil®, Penn Pharmaceuticals, Ltd., Tredegar, UK), which share the same antifungal spectrum
but differ in efficacy and toxicity [13,17]. The liposomal formulation (AmB-L) is constituted by
50–100 µm spheres, and is composed of hydrogenated phosphatidylcholine soy, 25% cholesterol,
sterically attached to distearylphosphatidyl glycerol (DSPG) and AmB. Every AmB molecule within
the liposome is complexed with DSPG and cholesterol, which allows it to escape the initial clearance
of the sarcoplasmatic reticulum; but once captured, the concentrations in the liver and spleen increase
as it decreases in the plasma. Consequently, it is guaranteed that there are no AmB-L residues in blood,
reaching the highest serum concentrations [13,18–22].
The first cases of resistance to polyenes’ treatment are related with the increase of systemic
infections, many of them with primary or intrinsic resistance to AmB and consistently associated
with high mortality rate [23–25]. These cases have been increasing, but fortunately the studies still
recognize the high effectiveness of AmB-Deox and AmB-L on planktonic cells or in the prevention of
the biofilm formation of Candida spp. [26–31]. On the other hand, fewer researchers have performed
studies specifically on the activity of the two formulations on matured biofilms [32,33]. Since these
communities are known to be responsible for the most aggressive systemic infections [2], the aim of
this study was to evaluate the efficacy of the AmB liposomal formulation (AmbiSome®) compared
to the original, deoxycholate (Fungizone®) in eliminating the cells derived from matured biofilms
of the four most common Candida spp. found in hospitals: Candida albicans, Candida glabrata,
Candida parapsilosis and Candida tropicalis.
2. Results and Discussion
The prevalence of invasive fungal infections will unquestionably continue to grow due to
the constant use of immunosuppressive and broadspectrum antimycotic therapy, the increase in
the number of patients at risk in medical care and particularly with the rise in the numbers of
severely immunocompromised patients [1,34–36]. Currently, echinocandins are considered the first-line
antifungals for treating systemic candidiasis [37,38]. Possibly as a result of this, both breakthrough
infections and acquired resistance mutations in certain Candida spp. have been reported (especially
for C. glabrata), which makes the management of invasive candidiasis a permanent challenge [39,40].
It is therefore vital to perform a constant assessment of whether antifungal drugs are still effective,
appropriate, and clinically safe. AmB, a polyene antifungal drug, binds to ergosterol, and also
induces the accumulation of reactive oxygen species, resulting in multiple deleterious and fungicidal
effects on fungal cells, which probably explains the low rate of resistance events associated with this
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drug [26,41]. Still, AmB also has the ability to bind to cholesterol, although with lower affinity,
which is assumed to be connected to its greater toxic potential. Due to the high frequency of
nephrotoxicity using AmB-Deox [42], the pharmaceutical industry has produced formulations with
lipids, namely AmB-L [13,43–45]. This work focused on Candida spp. infections resulting exclusively
from biofilm cells—which are recognized as having a great impact in nosocomial infections, although
they are still poorly understood [46]—and how they responded to two different formulations of AmB.
The results of MIC and MFC can be observed in Table 1. All four Candida spp. were considered
susceptible to both AmB formulations, according to the most recent EUCAST breakpoints [47].
Generally, AmB-Deox had a better performance than AmB-L in both tests, showing elimination of
spectrophotometric growth (MIC) or elimination, at least, of 2 Log10 CFU/cm2 of the initial inoculum
(MFC) at lower concentrations. With regard to the MIC results, C. tropicalis ATCC750 was the most
tolerant to AmB-Deox (0.5 mg/L, compared to the rest, 0.25 mg/L) and C. albicans SC5314 the most
sensitive to AmB-L (0.5 mg/L, compared to the rest, 1 mg/L). AmB-Deox is a colloidal dispersion with
a size of 0.035 nm, in contrast to the ~0.080 nm of size of the spherical AmB-L [13,48]. This fact probably
influenced the immediate cellular penetration in the free planktonic cells, enhancing it in the case
of the AmB-Deox, when comparing both formulations. In particular, for two of the studied species
(C. glabrata ATCC2001 and C. parapsilosis ATCC22019) AmB-L required a concentration 4 times higher
(1 mg/L) than that required when using AmB-Deox (0.25 mg/L). Similar results have been shown by
other authors regarding C. glabrata species [49–53]. C. albicans SC5314 was the species that demanded
the lowest drug concentrations, for both formulations, responding very well to this polyene, as it has
been indicated before [49,54–58]. With regard to the MFC results (Table 1), the differences between
the four species were not so evident. Generally, the concentration that points to the inhibition of growth
(MIC) is closer to cell death (MFC) for AmB-L than for AmB-Deox. Using AmB-L, the concentration
used for NCAC species was 1.5 times higher than for MIC; and for C. albicans SC5314, the value
was 3 times higher, showing a higher drug tolerance in this species, which has been demonstrated
previously [59]. With AmB-Deox, these variations were more noteworthy. In fact, it seems to have
an advantage in the use of AmB-L over AmB-Deox. These variations on Candida spp. responses
between AmB-Deox and AmB-L can determine the outcome in an infection treatment, especially in
biofilm infections, since it is known that the inhibition of growth does not always lead to cell death,
but sometimes to cell dormancy, or even the appearance of tolerant or persister cells [59–66]. None of
the drug formulations demanded high in vitro doses to show efficacy; thus, they were shown to be
good options for the treatment of planktonic Candida spp. infections.
Table 1. Results in MIC and MFC concentrations for both AmB formulations.
Species MIC (mg/L) MFC (mg/L)
AmB-Deox AmB-L AmB-Deox AmB-L
Candida albicans SC5314 0.25 0.5 1 1.5
Candida glabrata ATCC2001 0.25 1 1 1.5
Candida parapsilosis ATCC22019 0.25 1 1 1.5
Candida tropicalis ATCC750 0.5 1 1 1.5
Next, in order to visualize the appearance of the matured biofilms of the four Candida spp.,
SEM images were obtained (Figure 1). It was confirmed that all Candida spp. were able to form
structured biofilms under the culture conditions applied. Specifically, C. albicans SC5314 demonstrated
a biofilm with high hyphae quantity and entanglement [2,67]. This morphological change (from yeast
to hyphae) can influence biofilm formation and stability [2,68]. C. glabrata ATCC2001 formed biofilms
constituted by yeasts in a long continuous carpet [2,69,70] and C. parapsilosis ATCC22019 a continuous
biofilm carpet with clumped blastospores [2,71]. Finally, the C. tropicalis ATCC750 biofilm could
be described as chains of cells with high amounts of extracellular material [2,72,73]. These strong
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biofilms have been related to higher pathogenicity, virulence and resistance, and to difficulties in drug
diffusion [2,74–77].Pathogens 2017, 6, 62  4 of 13 
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doses for a systemic candidiasis (AmB-Deox: 1.2 mg/kg/day for an adult of 70 kg, and AmB-L: 6 
mg/kg/day [78,79]), in order to ease the comparison of the results, the data were transformed into 
percentage of maximum permitted daily dose (Table 2).  
Generally, AmB-L showed a better response on the 24-h-pre-formed biofilms. Excepting C. 
glabrata ATCC2001, the three other Candida spp. needed 2 mg/L of AmB-Deox to eliminate the biofilm 
cells, which represents approximately 12% of the maximum of the daily dose for this formulation. C. 
glabrata ATCC2001 presented a resistant pattern, requiring 4 mg/L (meaning almost 24% of the daily 
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cases with polyenes, have already been reported [30,80–83]. With AmB-L, the values were slightly 
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the maximum dose), followed by C. albicans SC5314, with 3 mg/L (3.57% of the maximum dose) (Table 
i r 1. SEM images of matured bi films of Candida albicans SC5314, Candida glabrata
ATCC2001, Candida parapsilosis ATC 22019 and Candida tropicalis ATCC750. Magnification: 1000×
(Measure bar = 20 µm).
With regard to the main goal of this study—the treatment and eradication of the biofilm
(MBEC, Table 2)—the outcomes changed significantly. Both AmB-L and AmB-Deox required
a drug concentration between 4 and 8 times greater to eliminate the biofilm cells compared to
the corresponding planktonic cells. Since AmB-Deox and AmB-L have very different permitted
daily doses for a systemic candidiasis (AmB-Deox: 1.2 mg/kg/day for an adult of 70 kg, and AmB-L:
6 mg/kg/day [78,79]), in order to ease the comparison of the results, the data were transformed into
percentage of maximum permitted daily dose (Table 2).
Generally, AmB-L showed a better response on the 24-h-pre-formed biofilms. Excepting C. glabrata
ATCC2001, the three other Candida spp. needed 2 mg/L of AmB-Deox to eliminate the biofilm cells,
which represents approximately 12% of the maximum of the daily dose for this formulation. C. glabrata
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ATCC2001 presented a resistant pattern, requiring 4 mg/L (meaning almost 24% of the daily dose),
which was not a total surprise, since for this species, this performance, as well as, resistance cases
with polyenes, have already been reported [30,80–83]. With AmB-L, the values were slightly more
variable. C. parapsilosis ATCC22019 was the least resistant species [47], with 2 mg/L (2.38% of
the maximum dose), followed by C. albicans SC5314, with 3 mg/L (3.57% of the maximum dose)
(Table 2). The MBEC values obtained were higher than previously reported for other C. albicans
strains [84–86], but were similar for C. parapsilosis [87,88]. The differences observed could be
due to alterations in the biofilm formation conditions, and the fact that the MBEC evaluations
methods used were not identical. Nonetheless, Prazynka and colleagues [30] had parallel outcomes
in 24-h-pre-formed biofilms. C. glabrata ATCC2001 and C. tropicalis ATCC750 presented a clearer
biofilm resistance profile, with results of ≥8 mg/L and ≥9.52% of the maximum dose (Table 2).
Comparable concentrations for these two species have already been reported by other authors [89–93].
It is noted, though, that when comparing the percentages of clinical doses, the required concentrations
to eliminate the biofilm are therapeutically more appealing when using AmB-L than AmB-Deox for all
Candida spp., since none of the determined concentrations of AmB-L even reached 10% of the maximum
daily dose (Table 2). The differences between the percentages of the two AmB formulations were
statistically significant for each species (p < 0.001).
Table 2. MBEC values of AmB-Deox and AmB-L and its percentage on the maximum permitted dose
used ‡.
Species
MBEC (mg/L)
AmB-Deox % of MaximumPermitted Dose # AmB-L
% of Maximum
Permitted Dose #
Candida albicans SC5314 2 11.90 3 3.57 ***
Candida glabrata ATCC2001 4 23.81 ≥8 ≥9.52 ***
Candida parapsilosis ATCC22019 2 11.90 2 2.38 ***
Candida tropicalis ATCC750 2 11.90 ≥8 ≥9.52 ***
‡ The difference between the percentages of both AmB formulations are all statistically significant; *** p < 0.001;
# Considered to be the maximum dose allowed for invasive candidiasis [78,79]: AmB-Deox—(0.6–1.2) mg/kg for
an adult of 70 kg; AmB-L—(3–6) mg/kg for an adult of 70 kg.
Finally, with regard to biofilm biomass reduction (Table 3), it was possible to observe a dependence
on species and AmB formulation; but generally, both AmBs were shown to have good performance,
with reductions between 34.64% and 89.58% for AmB-Deox, and between 43.78% and 70.72% for
AmB-L. C. tropicalis ATCC750 and C. albicans SC5314 showed a pronounced biofilm reduction, with only
0.25 mg/L of AmB-Deox (~90% and ~70%, respectively), but the MBEC values demonstrated that the
same biofilm cells required 8 times more drug concentration (2 mg/L) to be eliminated. The opposite
happened with C. glabrata ATCC2001 and C. parapsilosis ATCC22019. These two species demanded
a concentration near to the MBEC value to eliminate 50% of the biofilm, showing the capacity to
produce robust biofilms on abiotic surfaces, as has been previously described [94]. Regarding AmB-L,
C. albicans SC5314 was the species that required the lowest AmB-L concentration to eliminate the highest
percentage of its biomass (70.72%). In contrast, C. glabrata ATCC2001 needed a higher dose, confirming
the biofilm’s strong structure [95]. These findings have also been reported by other authors [90,96].
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Table 3. Percentage of biofilm reduction closer to 50 when using AmB-Deox and AmB-L for reference
species of C. albicans, C. glabrata, C. parapsilosis and C. tropicalis.
Species
[Drug] mg/L for Biofilm Reduction Closer to 50%
[AmB-Deox] % Max Biofilm Reduction [AmB-L] % Max Biofilm Reduction
Candida albicans SC5314 0.25 68.56 0.5 70.72
Candida glabrata ATCC2001 1.5 51.56 1.5 48.86
Candida parapsilosis ATCC22019 1.5 34.64 1 43.78
Candida tropicalis ATCC750 0.25 89.58 1 50.66
It is important to note that the obtained results regarding the biomass reductions do not match
the susceptibility determinations (planktonics and biofilms), since high biomass reductions were
obtained with lower (than MBEC) AmB concentrations for both formulations. It is known that,
in situations of drug stress, some species/strains block the production and exportation of certain biofilm
matrices’ compounds (e.g., proteins in C. glabrata) [97] and that, in these cases, subpopulation cells
with increased tolerance to AmB or even persister cells can arise, exclusively in the biofilms [61,63,98].
Although these facts are acknowledged, it is still widely admitted that the biofilm drug resistance in
Candida spp. remains to be totally explained, and is most likely multifactorial in nature.
3. Conclusions
In conclusion, compared with conventional amphotericin B, the liposomal formulation offers
a better safety profile in both adults and children, and accumulates in tissue, which is therapeutically
advantageous. Our results now show that AmB-L is a good option for the treatment of infections
directly associated with Candida spp. biofilm cells. Continuous clinical observations are essential to
measuring the activity of AmB-L against yeasts, in order to detect strains with low drug susceptibility,
thus supporting the most adequate choice of prompt antifungal treatment towards an improved
prognosis for the patient.
4. Material and Methods
4.1. Organisms and Growth Conditions
Four reference species of Candida spp., were used in this study: C. albicans SC5314, and three
from the American Type Culture Collection (ATCC), C. glabrata ATCC2001, C. parapsilosis ATCC22019
and C. Ttropicalis ATCC750. For each experiment, yeasts were subcultured on Sabouraud dextrose
agar (SDA) (Merck, Darmstadt, Germany) for 24 h at 37 ◦C. Cells were then inoculated in Sabouraud
dextrose broth (SDB) (Merck, Darmstadt, Germany) and incubated for 18 h at 37 ◦C under agitation at
120 rpm. After incubation, the cells were harvested by centrifugation at 3000× g for 10 min at 4 ◦C and
washed twice with phosphate-buffered saline (PBS, pH = 7.5). Pellets were then suspended in RPMI
1640 (Sigma-Aldrich, St. Louis, MO, USA) and the cellular density was adjusted to 1 × 105 cells/mL,
using a Neubauer counting chamber.
4.2. Antifungal Drugs
AmB-Deox was purchased from Sigma® (Sigma-Aldrich, St. Louis, MO, USA) and AmB-L
was supplied by Gilead® (Foster City, CA, USA). Aliquots of 2000 mg/L were prepared using
dimethyl-sulfoxide (DMSO) for AmB-Deox and of 1000 mg/L for AmB-L according to the indications
of the manufacturer.
4.3. Antifungal Susceptibility Tests
The antifungal susceptibility tests, for both formulations of AmB, were determined using
the microdilution method, in accordance with the European Committee on Antimicrobial Susceptibility
Testing guidelines [47].
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4.4. Planktonic Susceptibility Evaluation
4.4.1. Minimum Inhibitory Concentrations (MICs)
The AmB MIC is the lowest concentration, recorded in mg/L, of the drug that inhibits the growth
of the yeasts to a predefined degree (e.g., 90% in the case of polyenes) [99]. The MIC provides
information on the susceptibility or resistance of the Candida spp. to the AmB formulations [47,100].
The AmB concentrations tested were prepared in RPMI 1640 (pH = 7) (Sigma-Aldrich, St. Louis,
MO, USA). The inoculum was prepared by suspending five distinct colonies, ≥1 mm diameter from
24 h cultures, in at least 3 mL of sterile distilled water. Then, the inoculum was suspended by
vigorous shaking on a vortex mixer for 15 s and the cell density was adjusted to the density of
a 0.5 McFarland standard, adding sterile distilled water as required, giving a yeast suspension of
1–5 × 106 colony-forming units (CFUs) CFU/mL. A working suspension was prepared by a dilution
of the standardised suspension in sterile distilled water to yield 1–5 × 105 CFU/mL. The 96-well plate
was prepared with 100 µL of cell suspension and 100 µL of antifungal agent (0.25, 0.5, 1 and 1.5 mg/L,
2× concentrated) and incubated at 37 ◦C, during 18–48 h. Controls without antifungal agents were
also performed. Finally, the results were visualized by spectrophotometry at 530 nm.
4.4.2. Minimum Fungicidal Concentration (MFC)
The AmB MFC is the lowest concentration, recorded in mg/L, of the drug that reduces
the planktonic population to at least 2 Log10 CFU per cm2. For that determination, in addition
to the previous step, 20 µL of each cell suspension treated with AmB-Deox and AmB-L was recovered
and placed in a new well, and serial decimal dilutions in phosphate-buffered saline (PBS 0.1 M pH 7.5)
were plated onto SDA. Agar plates were incubated for 24 h at 37 ◦C, and the total number of CFUs
was determined. The results were calculated by Log10 CFU per cm2 (Log10 CFUs/cm2) and presented
by mg/L [101].
4.5. Biofilm Structure, Susceptibility Evaluation and Biomass Reduction Analysis
4.5.1. Scanning Electronic Microscopy (Biofilm Structure Visualization)
In order to examine the structure of the biofilms of the Candida spp., they were observed by
scanning electron microscopy. For this, the biofilms formed as described above were dehydrated with
ethanol (using 70% ethanol for 10 min, 95% ethanol for 10 min and 100% ethanol for 20 min) and
air-dried for 20 min. Samples were kept in a desiccator until the base of the wells was removed
for analysis. Prior to observation, the bases of the wells were mounted onto aluminum stubs,
sputter-coated with gold, and observed with an S-360 scanning electron microscope (Leo, Cambridge,
MA, USA).
4.5.2. Minimum Biofilm Eradication Concentration (MBEC)
The AmB MBEC is the lowest concentration, recorded in mg/L, of the drug able to reduce
the biofilm cell population to at least 2 Log10 CFU per cm2. For this determination, standardized cell
suspensions (200 µL) were placed into selected wells of 96-well polystyrene microtiter plates (Orange
Scientific, Braine-l’Alleud, Belgium). RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA) was used
without cells, but with antifungal agent, as a negative control. As positive control, cell suspensions
were tested without antifungal agent. At 24 h, 100 µL of RPMI 1640 (Sigma-Aldrich, St. Louis,
MO, USA) was removed, and an equal volume of fresh RPMI 1640 plus the respective antifungal
concentration was added (2, 3, 4, 8 mg/L, 2× concentrated). The plates were incubated at 37 ◦C for
another 24 h, a total of 48 h at 120 rpm. The number of cultivable cells on biofilms was determined by
the enumeration of CFUs. For this, after the period of biofilm formation, all medium was aspired, and
the biofilms were washed once with 200 µL of PBS to remove non-adherent cells. Then, biofilms were
scraped from the wells, and the suspensions were vigorously vortexed for 2 min to disaggregate
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the cells from the matrix. Serial decimal dilutions in PBS were plated on SDA and incubated for 24 h at
37 ◦C. The results were calculated as a total of CFUs per unit area (Log10 CFUs/cm2), and presented
by mg/L [101].
4.5.3. Biofilm Total Biomass Quantification—Crystal Violet Staining
Total biofilm biomass was quantified by crystal violet (CV) staining [102]. After biofilm formation,
the medium was aspirated, and non-adherent cells removed by washing the biofilms with sterile
ultra-pure water. Then, biofilms were fixed with 200 µL methanol, which was removed after 15 min of
contact. The microtiter plates were allowed to dry at room temperature, and 200 µL of CV (1% v/v)
were added to each well and incubated for 5 min. The wells were then gently washed twice with
sterile, ultra-pure water and 200 µL of acetic acid (33% v/v) were added to release and dissolve
the stain. The absorbance of the obtained solution was read in triplicate in a microtiter plate reader
(Bio-Tek Synergy HT, Izasa, Lisbon, Portugal) at 570 nm. Three negatives were performed using sterile
ultra-pure water. The results were presented as percentage of reduction of biomass.
4.6. Statistical Analysis
The assays were performed in triplicate, and on three separate occasions. Results were compared
using two-way ANOVA, and Bonferroni’s post-test, using GraphPad Prism 5 software. All tests were
performed with a confidence level of 95%.
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